Should anti-CD20 be used as an immune reconstitution therapy?
Open Access
- 13 July 2022
- journal article
- letter
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 29 (2) , 308-310
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of AlemtuzumabJAMA Neurology, 2017
- Both cladribine and alemtuzumab may effect MS via B-cell depletionNeurology Neuroimmunology & Neuroinflammation, 2017
- Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisNew England Journal of Medicine, 2017
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe Lancet, 2012
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 2012
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trialArthritis & Rheumatism, 2009
- Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trialAnnals of Neurology, 2008
- Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trialNeurology, 1997